Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30321054 | 0.87 | MAPK14 (0.38) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL25793267 | 0.81 | MAPK14 (0.39) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL24096657 | 0.80 | ALDH1A1 (0.39) | MAPK14ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL25793255 | 0.80 | ALDH1A1 (0.45) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL9893071 | 0.79 | MAPK14 (0.56) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL10806751 | 0.77 | CA2 (0.44) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL28720799 | 0.75 | LMNA (0.44) | CA2CA7CA1CA4ALDH1A1 | |
| SCHEMBL9893070 | 0.74 | MAPK14 (0.47) | CA2CA7CA1CA4MAPK14 | |
| SCHEMBL4882325 | 0.73 | CNR2 (0.39) | ACACBCNR2 | |
| SCHEMBL4853136 | 0.72 | PPARA (0.38) | ALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203045-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | CA2 4180/4885CA7 2888/4885CA1 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.